A Safety Study of NNZ-2566 in Patients With Rett Syndrome

NCT01703533 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Rett Syndrome

Interventions

DRUG: NNZ-2566
DRUG: Placebo

Sponsor

Neuren Pharmaceuticals Limited

Collaborators

[object Object]
[object Object]